2024
MDS-772 Time Toxicity for Patients Receiving Oral Versus Parenteral Hypomethylating Agents for Myelodysplastic Syndromes/Neoplasms
Zeidan A, Olopoenia A, Costantino H, Modi K, Salimi T, Washington T, Krenitsky J, Epstein R. MDS-772 Time Toxicity for Patients Receiving Oral Versus Parenteral Hypomethylating Agents for Myelodysplastic Syndromes/Neoplasms. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s406. DOI: 10.1016/s2152-2650(24)01382-x.Peer-Reviewed Original ResearchHMA therapyRetrospective analysis of adult patientsAnalysis of adult patientsRoute of administrationMedian life expectancyPropensity score matchingHypomethylating agentsMDS treatmentBurden of treatmentAdult patientsPatient cohortInfusion dayParenteral treatmentMatched cohortResults PatientsRetrospective analysisOlder patientsEmergency room visitsCancer therapyHMA treatmentParenteral administrationTherapyPatientsOutpatient settingScore matching
2013
Effect of availability of oral iron chelation therapy (ICT) on initiation, duration, and dose adequacy in patients with myelodysplastic syndromes (MDS) and transfusional iron overload (TIO).
Gore S, Davidoff A, Hendrick F, Duong V, Stuart B, Baer M, Shenolikar R, Zeidan A. Effect of availability of oral iron chelation therapy (ICT) on initiation, duration, and dose adequacy in patients with myelodysplastic syndromes (MDS) and transfusional iron overload (TIO). Journal Of Clinical Oncology 2013, 31: e17584-e17584. DOI: 10.1200/jco.2013.31.15_suppl.e17584.Peer-Reviewed Original ResearchOral iron chelation therapyIron chelation therapyTransfusional iron overloadMyelodysplastic syndromeDose adequacySupportive care drugsProportional hazards modelMedicare Part ATherapeutic equipoiseCohort entryHazard ratioMost patientsRBC transfusionMDS patientsOral chemotherapyAdequate doseCare drugsIron overloadLogistics of administrationChelation therapyOral formulationHazards modelMedicare beneficiariesParenteral administrationTreatment duration